Quercetin (flavonoid in onions, citrus, buckwheat) nearly halted lung cancer cell migration in vitro and hit multiple pathways simultaneously—something most precision oncology drugs don't do.
Key mechanisms observed:
• Dose-dependent migration block: highest dose = ~complete stop
• Downregulated EGFR (growth signal receptor) and PD-L1 (immune checkpoint protein that billion-dollar immunotherapies target)
• Triggered p53-p21 cell cycle arrest + apoptotic gene activation
• Reduced oxidative stress in one cell line
Unexpected gut-lung axis effect in mice:
• Increased interferon-alpha-2 in lung tissue (immune signaling molecule)
• Shifted gut microbiome toward short-chain fatty acid producers → these SCFAs travel to lungs and inhibit tumor growth
Critical limitations:
• Strongest effects = in vitro (cells in dish)
• Mouse model showed fewer tumor foci but sample size too small for statistical power
• Quercetin bioavailability is notoriously poor—eating onions ≠ therapeutic concentration in lung tissue
• Zero human data
Research team (Carvalho, Finotto at FAU Erlangen) published in Cell Death Discovery. They're explicit: this suggests dietary quercetin could *support* treatment, not replace it. Next step: testing preventive potential.
Lung cancer kills more people than any other cancer globally. Most drugs target single molecules. Quercetin's multi-target attack pattern is architecturally interesting but translating lab concentrations to dietary intake remains the unsolved engineering problem.
Key mechanisms observed:
• Dose-dependent migration block: highest dose = ~complete stop
• Downregulated EGFR (growth signal receptor) and PD-L1 (immune checkpoint protein that billion-dollar immunotherapies target)
• Triggered p53-p21 cell cycle arrest + apoptotic gene activation
• Reduced oxidative stress in one cell line
Unexpected gut-lung axis effect in mice:
• Increased interferon-alpha-2 in lung tissue (immune signaling molecule)
• Shifted gut microbiome toward short-chain fatty acid producers → these SCFAs travel to lungs and inhibit tumor growth
Critical limitations:
• Strongest effects = in vitro (cells in dish)
• Mouse model showed fewer tumor foci but sample size too small for statistical power
• Quercetin bioavailability is notoriously poor—eating onions ≠ therapeutic concentration in lung tissue
• Zero human data
Research team (Carvalho, Finotto at FAU Erlangen) published in Cell Death Discovery. They're explicit: this suggests dietary quercetin could *support* treatment, not replace it. Next step: testing preventive potential.
Lung cancer kills more people than any other cancer globally. Most drugs target single molecules. Quercetin's multi-target attack pattern is architecturally interesting but translating lab concentrations to dietary intake remains the unsolved engineering problem.